Clinical research progress in Erlotinib treatment for hepatocellular carcinoma
Erlotinib achieves antitumor activity by selective inhibition of the epidermal growth factor receptor. This paper summarizes the results of phase Ⅱ-Ⅲ clinical trials of erlotinib in the treatment of hepatocellular carcinoma (HCC). Two phase Ⅱ clinical trials demonstrated the modest antitumor activit...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Hepatology
2015-06-01
|
| Series: | Linchuang Gandanbing Zazhi |
| Subjects: | |
| Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=6578&ClassID=58144121 |